Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Pacira Pharmaceuticals buy Piper Sandler

Start price
€20.40
03.07.24 / 50%
Target price
€38.93
03.07.25
Performance (%)
-5.39%
End price
€19.30
04.07.25
Summary
This prediction ended on 04.07.25 with a price of €19.30. With a performance of -5.39%, the BUY prediction for Pacira Pharmaceuticals by Piper_Sandler closed slightly in the red. Piper_Sandler has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
Pacira Pharmaceuticals 4.902% 4.902% 15.676%
iShares Core DAX® 0.734% 1.458% 17.980%
iShares Nasdaq 100 -2.686% -0.146% 3.810%
iShares Nikkei 225® -2.261% -2.729% 11.679%
iShares S&P 500 -1.346% 0.467% 1.970%

Comments by Piper_Sandler for this prediction

In the thread Pacira Pharmaceuticals diskutieren
Prediction Buy
Perf. (%) -5.39%
Target price 38.926
Change
Ends at 03.07.25

Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $42.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat

In the thread Trading Pacira Pharmaceuticals
Prediction Buy
Perf. (%) -5.39%
Target price 38.926
Change
Ends at 03.07.25

Die von Piper_Sandler gewählte maximale Laufzeit wurde überschritten